Monoclonal Antibodies as Targeted Therapies in Advanced or Recurrent Endometrial Cancer: A Systematic Review

• DOI: https://doi.org/10.22533/at.ed.159532509015

• Palavras-chave: Endometrial cancer; Monoclonal antibodies; Targeted therapies; Immunotherapy; Systematic review

• Keywords: Endometrial cancer; Monoclonal antibodies; Targeted therapies; Immunotherapy; Systematic review

• Abstract:

  Introduction: Advanced or recurrent endometrial cancer presents considerable therapeutic challenges, with limited options and an unfavorable prognosis. The development of target therapies, such as monoclonal antibodies, has emerged as a promising alternative for the treatment of this disease. Objective: This study aimed to conduct a comprehensive systematic review of clinical trials investigating the use of monoclonal antibodies in the treatment of advanced or recurrent endometrial cancer. The main focus was to elucidate the mechanisms of action, identify potential side effects and evaluate the clinical efficacy and therapeutic results of these therapies. Methods: The search for relevant articles was conducted in the PubMed, Embase and Scopus databases, covering the period from 1982 to 2023. Only human studies, randomized or not, in phase II or III, written in English, using the descriptors "monoclonal", "antibody", "endometrial" and "cancer" were included. The selection of studies and data extraction were carried out by four independent reviewers, following the guidelines of the PRISMA protocol. Results: The initial search resulted in the identification of 2069 articles, of which 25 were included in the final review after applying the eligibility criteria. The results showed that the use of monoclonal antibodies, such as pembrolizumab, dostarlimab, avelumab and durvalumab, resulted in significant improvements in overall survival (OS) and progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, especially in those with MSI-H/dMMR tumors. Conclusions: Monoclonal antibodies represent a promising class of targeted therapies for advanced or recurrent endometrial cancer, with the potential to improve patients' clinical outcomes. However, more studies are needed to define the optimal role of each antibody and identify the best therapeutic combinations, taking into account the individual molecular profile of each patient.